• Home
  • Articles
  • Global News
  • Interest
  • Global Events
    • Add Event
  • Health Tips
  • Knowledge
    • Drug Directory
    • Education
      • Pharmacy Case Study
      • Pharmacy eBook Reviews
    • Pharma Companies
    • Dictionary Online
    • Career
    • Pharma Video
    • Featured Pharma Leader
  • About
    • Contact Us
    • Write for Us
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Email

Pharma Mirror Magazine

Mobile Logo

Browse Tag

AIM ImmunoTech

AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus
Pharmaceutical News

AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus

February 11, 2020February 11, 2020

AIM ImmunoTech Inc. (NYSE American:AIM) announced the filing of three provisional patent applications related to its drug candidate Ampligen in

More

Subscribe

Subscribe our Articles, please enter your email below:

Please verify the email sent to your inbox to complete the subscription process. It's safe and free too.

Recent Posts

  • 5 Ways We Can Help Healthcare Workers in the Fight Against COVID-19 July 10, 2020
  • How to Manage Chronic Pain During the Lockdown? July 9, 2020
  • Avance Clinical Wins Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award July 9, 2020
  • First New Drug Application for Dayvigo in Asia outside Japan July 9, 2020
  • Evaporation Index – The Key to Excellence in Execution July 8, 2020

Free Version Works Great Too!

Free gr

  • Facebook
  • Twitter
  • LinkedIn
  • Email

© 2010-2020 PharmaMirror.com - All Rights Reserved.

  • Home
  • Articles
  • Global News
  • Interest
  • Global Events
    • Add Event
  • Health Tips
  • Knowledge
    • Drug Directory
    • Education
      • Pharmacy Case Study
      • Pharmacy eBook Reviews
    • Pharma Companies
    • Dictionary Online
    • Career
    • Pharma Video
    • Featured Pharma Leader
  • About
    • Contact Us
    • Write for Us
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Email
Go toTop